Yu Rucui, Wu Ruiying, Chen Tingting, Zhang Yan, Chen Xiangqing
Department of Traditional Chinese Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, People's Republic of China.
Department of Anorectal, 901 Hospital of Joint Service Support Force of PLA, Hefei, 230031, People's Republic of China.
Diabetes Metab Syndr Obes. 2025 Jun 28;18:2041-2055. doi: 10.2147/DMSO.S523784. eCollection 2025.
This study used network pharmacology to explore how Yiqi Yangyin Tongluo Formula (YQYTLF) alleviates diabetic nephropathy (DN), focusing on the AGE-RAGE signaling pathway.
Active compounds and targets of YQYTLF were identified via TCMSP, and a herb-compound-target network was constructed using Cytoscape. Differentially expressed genes from DN kidney tissues (GEO dataset GSE104948) were intersected with drug targets for KEGG and GO enrichment analysis. Protein-protein interaction (PPI) networks were analyzed in STRING and visualized in Cytoscape. A DN rat model was treated with YQYTLF, with weekly monitoring of body weight, food and water intake. Fasting blood glucose (FBG), insulin (FINS), serum creatinine (Scr), blood urea nitrogen (BUN), and urinary albumin excretion rate (UAER) were measured. HOMA-β and HOMA-IR assessed beta cell function and insulin resistance. Kidney pathology was evaluated by HE and Sirius Red staining. Kidney tissue levels of AGEs, oxidative stress markers (ROS, MDA, GSH, SOD), and RAGE expression (by WB) were analyzed. Molecular docking assessed binding between active compounds and core targets.
Network pharmacology identified 13 core targets, 8 enriched in the AGE-RAGE pathway. YQYTLF significantly reduced FBG, FINS, Scr, BUN, UAER, HOMA-IR, renal index, and pruritus while improving HOMA-β in DN rats. Renal pathological changes including Bowman's capsule dilation, mesangial proliferation, and fibrosis were alleviated. YQYTLF inhibited kidney AGEs, oxidative stress, and RAGE expression. Molecular docking confirmed strong binding between active ingredients and core targets.
YQYTLF alleviates DN in rats by inhibiting AGE-RAGE pathway activation and reducing oxidative stress, providing a theoretical basis for DN therapy.
本研究运用网络药理学探讨益气养阴通络方(YQYTLF)如何缓解糖尿病肾病(DN),重点关注晚期糖基化终末产物-受体(AGE-RAGE)信号通路。
通过中药系统药理学数据库与分析平台(TCMSP)鉴定YQYTLF的活性成分和靶点,使用Cytoscape构建“药物-成分-靶点”网络。将DN肾组织的差异表达基因(GEO数据集GSE104948)与药物靶点进行交集分析,以进行京都基因与基因组百科全书(KEGG)和基因本体论(GO)富集分析。在STRING中分析蛋白质-蛋白质相互作用(PPI)网络,并在Cytoscape中进行可视化。用YQYTLF治疗DN大鼠模型,每周监测体重、食物和水摄入量。测量空腹血糖(FBG)、胰岛素(FINS)、血清肌酐(Scr)、血尿素氮(BUN)和尿白蛋白排泄率(UAER)。采用稳态模型评估法的β细胞功能指数(HOMA-β)和胰岛素抵抗指数(HOMA-IR)评估β细胞功能和胰岛素抵抗。通过苏木精-伊红(HE)和天狼星红染色评估肾脏病理学变化。分析肾脏组织中晚期糖基化终末产物(AGEs)、氧化应激标志物(活性氧(ROS)、丙二醛(MDA)、谷胱甘肽(GSH)、超氧化物歧化酶(SOD))水平以及RAGE表达(通过蛋白质免疫印迹法(WB))。分子对接评估活性成分与核心靶点之间的结合。
网络药理学鉴定出13个核心靶点,其中8个在AGE-RAGE通路中富集。YQYTLF显著降低DN大鼠的FBG、FINS、Scr、BUN、UAER、HOMA-IR、肾指数和瘙痒,同时改善HOMA-β。缓解了包括肾小球囊扩张、系膜增生和纤维化在内的肾脏病理变化。YQYTLF抑制肾脏AGEs、氧化应激和RAGE表达。分子对接证实活性成分与核心靶点之间有强结合。
YQYTLF通过抑制AGE-RAGE通路激活和减轻氧化应激来缓解大鼠DN,为DN治疗提供理论依据。